EIK1001 added to pembrolizumab and chemotherapy for advanced non-small cell lung cancer
Tests EIK1001 with pembrolizumab and chemotherapy in adults with advanced non-small cell lung cancer.
Key facts
- Who runs it
- Eikon Therapeutics
- Where
- George and Saxonwold, South AfricaSee the 2 sitesAlso in 17 other countries, 80 sites
- Trial code
- Registry title
- A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
- Status
- Recruiting
- Phase
- Phase 2/3
- People taking part
- 750 people, planned
- Started
- 15 Jun 2026
- Expected to end
- 31 Dec 2040
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- EIK1001
- Pembrolizumab (KEYTRUDA®)
- Placebo
- Paclitaxel + Carboplatin
- Nab-paclitaxel + Carboplatin
- Pemetrexed + Cisplatin /Carboplatin
- Record updated
- 16 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with stage 4 non-small cell lung cancer (squamous or non-squamous) who have not yet had drug treatment for advanced disease.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Stage 4 non-small cell lung cancer, mostly squamous or non-squamous, with at least 1 measurable lesion. Life expectancy of at least 3 months.
- Earlier treatment
- No earlier drug treatment for advanced or metastatic lung cancer. Treatment given after or before surgery or radiation can count if the cancer came back more than 1 year after it ended.
- Biomarker or test result
- Tests must show no tumor mutations or fusions (for example EGFR, ALK, RET, ROS1, BRAF) that have an approved first-line targeted therapy. Tumor tissue must be available for PD-L1 testing.
Main reasons for not taking part
- Small cell elements in the tumor, or tumors that are not mostly squamous or non-squamous
- Investigational therapy within 4 weeks or 5 half-lives (whichever is longer) of EIK1001 or placebo
- Major surgery less than 3 weeks before the first dose
- Live-virus vaccine within 30 days before starting
- Radiation therapy within 7 days before the first dose
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Participant must be ≥ 18 years old at the time of signing the informed consent
- Participant has a life expectancy of at least 3 months
- Participant has histologically or cytologically confirmed Stage 4 NSCLC predominately squamous or non-squamous) and is considered a candidate for standard therapy with pembrolizumab and chemotherapy. Participants with NSCLC-NOS (not otherwise specified) will be considered as non-squamous NSCLC
- Participant must have documented evidence that mutation-directed therapy is not indicated, based on the absence of tumor-activating mutations or fusions (e.g., but not limited to EGFR, ALK, RET, ROS1, BRAF) for which approved first-line targeted therapies are available to the participant in their respective country
- Participant has at least 1 lesion with measurable disease at Baseline according to RECIST 1.1 as determined locally. Lesions situated in a previously irradiated area are considered measurable if progression has been shown in such lesions
- Participant has not received prior systemic therapy for advanced/metastatic NSCLC; Note: Participants who received adjuvant or neoadjuvant treatment (after surgery and/or radiation therapy) and developed recurrent or metastatic disease more than 1 year after completing therapy are eligible
- Participant has an ECOG Performance Status of 0 to 1 assessed no more than 10 days before start of the treatment
- Participant has tumor tissue available for PD-L1 testing from a site that was not radiated prior to biopsy, and was obtained, ideally, after diagnosis of metastatic disease. Biopsies obtained prior to receipt of adjuvant/neoadjuvant chemotherapy will be permitted if recent biopsy is not feasible (provided the specimen is < 3yrs old)
Who cannot take part
- is currently actively enrolled in or has recently participated in a study of an investigational agent and received investigational therapy within 4 weeks or 5 half-lives (whichever is longer) of administration of EIK1001 or placebo
- has had major surgery (< 3 weeks prior to the first dose of study intervention administration)
- has received a live-virus vaccination within 30 days of the start of study intervention initiation
- has received radiation therapy within 7 days of the first dose of study intervention administration
- has completed palliative radiotherapy within 7 days of the first dose of study intervention administration
- has small cell elements present histologically and/or the tumors are not predominantly non-squamous or squamous NSCLC
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
The criteria questions were written by an AI system from the criteria published for NCT07365319. Checked by software, not by a doctor.
- Which best describes your lung cancer?
- Has the cancer spread to other parts of the body, or is it too advanced to be removed by surgery?
This trial is currently available in South Africa.
Also in 17 other countries, 80 sites
- Task EdenGeorge, South AfricaContact: Elelta ShiferrawTaking people
- The Medical Oncology Centre of RosebankSaxonwold, South AfricaContact: Elelta ShiferrawTaking people
About the trial
What the trial wants to find out
This is a study to evaluate the safety and efficacy of EIK1001 administered intravenously in combination with pembrolizumab and histologically appropriate chemotherapy for patients with stage 4 NSCLC.
The 3 groups in the trial
- Arm 1 (Placebo in Combination with SOC)Placebo, for comparison
Participants in this arm will receive EIK1001 Placebo + Standard of Care (SOC).
Treatment: Pembrolizumab (KEYTRUDA®), Placebo, Paclitaxel + Carboplatin, Nab-paclitaxel + Carboplatin, and Pemetrexed + Cisplatin /Carboplatin
- Arm 2 (EIK1001 in Combination with SOC)Treatment being tested
Participants in this arm will receive EIK1001 (Selected Dose 1) + Standard of Care (SOC).
Treatment: EIK1001, Pembrolizumab (KEYTRUDA®), Paclitaxel + Carboplatin, Nab-paclitaxel + Carboplatin, and Pemetrexed + Cisplatin /Carboplatin
- Arm 3 (EIK1001 in Combination with SOC)Treatment being tested
Participants in this arm will receive EIK1001 (Selected Dose 2) + Standard of Care (SOC).
Treatment: EIK1001, Pembrolizumab (KEYTRUDA®), Paclitaxel + Carboplatin, Nab-paclitaxel + Carboplatin, and Pemetrexed + Cisplatin /Carboplatin
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer (TeLuRide-008).
- Plain-language title
- EIK1001 added to pembrolizumab and chemotherapy for advanced non-small cell lung cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Criteria questions
- Built from NCT07365319, who can take part
- Record updated
- 16 November 2026